1型糖尿病胰岛素泵与每日多次注射的真实世界成本:瑞典国家糖尿病登记研究
基于瑞典国家糖尿病登记2005-2013年数据,纳入14,238例1型糖尿病患者(泵4,991例,MDI 9,247例),采用2:1时变倾向评分匹配。泵治疗年均成本高于MDI(12,928 vs 9,005美元,P<0.001;平均差3,923美元[95%CI 3,703-4,143])。
要点
- 泵治疗年均成本比MDI高3,923美元(95%CI 3,703-4,143)。
- 医疗成本(含药物和耗材)占泵治疗总成本的73%,MDI为63%。
- 低教育、低收入、女性及高龄者成本更高。
核心结论
- 在真实世界中,成人1型糖尿病泵治疗的年均成本显著高于MDI治疗。
研究设计与样本
- 基于瑞典国家糖尿病登记的人群队列,泵治疗者与MDI按2:1时变倾向评分匹配,分析2005-2013年全国登记数据。
主要发现
- 泵治疗年均成本12,928美元,MDI为9,005美元,差异3,923美元(95%CI 3,703-4,143;P<0.001)。
- 医疗成本占泵治疗总成本的73%,占MDI总成本的63%。
- 低教育、低可支配收入、女性及高龄与更高成本相关。
关键数值与推荐
- 共纳入14,238例1型糖尿病患者,其中泵治疗4,991例,MDI 9,247例。
- 基线平均年龄34岁,糖尿病病程21年,平均HbA1c 8.1%(65 mmol/mol)。
- 观察73,920人年,平均随访5年。
临床怎么用
- 在资源分配决策中需考虑泵治疗相对于MDI的额外成本,并结合其获益综合评估。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 成本分析基于瑞典登记数据,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate real-world costs of continuous insulin pump therapy compared with multiple daily injection (MDI) therapy for type 1 diabetes. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes and pump therapy in the Swedish National Diabetes Register (NDR) since 2002 were eligible. Control subjects on MDI were matched 2:1 using time-varying propensity scores. Longitudinal data on health care resource use, antidiabetes treatment, sickness absence, and early retirement were taken from national registers for 2005-2013. Mean annual costs were analyzed using univariate analysis. Regression analyses explored the role of sociodemographic factors. Subgroup and sensitivity analyses were performed. RESULTS: A total of 14,238 individuals with type 1 diabetes entered in the NDR between 2005 and 2013 (insulin pump n = 4,991, MDI n = 9,247, with switches allowed during the study) were included. Mean age at baseline was 34 years, with 21 years of diabetes duration and a mean HbA1c of 8.1% (65 mmol/mol). We had 73,920 person-years of observation with a mean follow-up of 5 years per participant. Mean annual costs were higher for pump therapy than for MDI therapy ($12,928 vs. $9,005, respectively; P < 0.001; mean difference $3,923 [95% CI $3,703-$4,143]). Health care costs, including medications and disposables, accounted for 73% of the costs for pump therapy and 63% of the costs for MDI therapy. Regression analyses showed higher costs for low education, low disposable income, women, and older age. CONCLUSIONS: Nine years of real-world data on all measurable diabetes-related resource use show robust results for additional costs of insulin pump therapy in adults by subgroup and alternative propensity score specifications. Identification of tangible and intangible benefits of pump therapy over time remain important to support resource allocation decisions.
引用
- Toresson Grip E, Svensson AM, Miftaraj M, et al. Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register. Diabetes Care. 2019. PMID: 30705062. doi:10.2337/dc18-1850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。